带状血管疾病:以前未被识别的状细胞疾病的表现?
Pari Jafari1, Gertruda Evaristo2, Xiaotang Alison Du3
1Department of Pathology, University of Chicago Medicine, The University of Chicago, Chicago, Illinois.
概括
带状血管疾病 (PSVD) 经常在状细胞病患者中发现,这可能解释肝脏功能障碍. 在状细胞疾病中早期识别PSVD可能有助于管理门腔高血压并发症.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 血管病理学血管病理学
- 血液学 血液学 血液学
背景情况:
- 带状血管疾病 (PSVD) 是一种涉及肝脏微血管病变的基因病学实体.
- 脊髓灰质炎已与各种疾病有关,但在状细胞疾病 (SCD) 中以前没有描述过.
- SCD的特点是微血管功能障碍和已知的肝损伤模式.
研究的目的:
- 调查状细胞疾病中PSVD的流行和发病因子.
- 为了确定PSVD是否有助于SCD患者的肝功能障碍.
主要方法:
- 从SCD患者的41个肝脏活检的回顾性分析.
- 对PSVD特征进行组织病理学评估.
- 对于·维勒布兰德因子,CD34和谷氨酸合成酶的免疫组合化学染色.
主要成果:
- 在SCD患者中,90.2%符合PSVD诊断标准.
- 异常的CD34 (97.2%) 和·威莱布兰德因子 (86.1%) 染色是常见的.
- 在3区肝细胞中减少了谷氨酸合成酶的活性,在52.8%的病例中观察到.
结论:
- 在状细胞疾病中,PSVD非常普遍.
- 慢性发病可能导致门微血管重塑,导致PSVD和3区肝细胞回归.
- 在SCD中,PSVD可能解释肝功能障碍,并且需要对门门高血压进行监测.
相关概念视频
Hepatic Portal System
1.4K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
1.4K
Pulmonary Hypertension: Classification and Pathogenesis
194
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
194
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
14
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
14
Multiple Allele Traits
34.3K
The Concept of Multiple Allelism
34.3K
Cystic Fibrosis: Pathogenesis
256
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
256
Disorders of Hemostasis
968
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
968


